Advertisement

Reduced diffusing capacity for carbon monoxide predicts borderline pulmonary arterial pressure in patients with systemic sclerosis

  • Keita Ninagawa
  • Masaru KatoEmail author
  • Hiroyuki Nakamura
  • Nobuya Abe
  • Michihito Kono
  • Yuichiro Fujieda
  • Kenji Oku
  • Shinsuke Yasuda
  • Hiroshi Ohira
  • Ichizo Tsujino
  • Tatsuya Atsumi
Observational Research
  • 27 Downloads

Abstract

Early intervention in pulmonary arterial hypertension associated with systemic sclerosis (SSc) may improve its prognosis. We aimed to establish an algorithm to detect mean pulmonary artery pressure (mPAP) > 20 mmHg using non-invasive examinations in SSc patients by modifying the DETECT algorithm. This study included SSc patients who underwent right heart catheterization (RHC) in our hospital during 2010–2018. Following variables were assessed for performance to predict mPAP ≥ 25 mmHg or > 20 mmHg; anti-centromere or U1-RNP antibody, plasma BNP level, serum urate level, right axis deviation, forced vital capacity (FVC)/diffusing capacity for carbon monoxide (DLCO) ratio, and tricuspid regurgitation velocity. Of 58 patients enrolled in this study, 24 had mPAP of ≥ 25 mmHg and 9 had mPAP of 21–24 mmHg. Among variables tested, only FVC/DLCO elevated similarly in patients with mPAP of ≥ 25 mmHg (median 2.5) and those with mPAP of 21–24 mmHg (median 2.5) compared to those with mPAP of ≤ 20 mmHg (median 1.5). Given the particularly good correlation between DLCO and mPAP of > 20 mmHg, each variable was weighted according to its odds ratio and the total weighted score was calculated. The total weighted score exhibited a good predictive performance for mPAP of > 20 mmHg with its sensitivity of 87.5% and specificity of 92%. Among conventional risk factors for PAH, decreased DLCO may predict mPAP > 20 mmHg with priority in SSc patients. Weighting DLCO may improve the performance of screening algorithm for early SSc-PAH.

Keywords

Pulmonary arterial hypertension Systemic sclerosis Screening FVC/DLCO 

Notes

Acknowledgements

No specific funding was received to carry out the work described in this manuscript.

Author contributions

All authors were involved in drafting the manuscript or revising it critically for important intellectual content, and approved the final version to be submitted for publication. MK had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study conception and design: HN and MK. Acquisition of data: KN, HN, NA, HO, and IT. Analysis and interpretation of data: KN, HN, MK, YF, KO, SY, and TA.

Compliance with ethical standards

Conflict of interest

No specific funding was received to carry out the work described in this manuscript. TA reports personal fees from Chugai, during the conduct of the study; grants and personal fees from Astellas, grants and personal fees from Takeda, grants and personal fees from Mitsubishi Tanabe, grants and personal fees from Chugai, grants and personal fees from Pfizer, grants from Daiichi Sankyo, grants from Otsuka, personal fees from Eisai, and personal fees from AbbVie, outside the submitted work. SY reports grants and speaker’s fee from Bristol-Myers Squibb Co., Speaker’s fee from Chugai, Mitsubishi Tanabe, outside the submitted work. MK reports grants from GSK, grants from Actelion, outside the submitted work. The other authors state that they have no conflict of interest. TA reports personal fees from Chugai, during the conduct of the study; grants and personal fees from Astellas, grants and personal fees from Takeda, grants and personal fees from Mitsubishi Tanabe, grants and personal fees from Chugai, grants and personal fees from Pfizer, grants from Daiichi Sankyo, grants from Otsuka, personal fees from Eisai, and personal fees from AbbVie, outside the submitted work. SY reports grants and speaker’s fee from Bristol-Myers Squibb Co., Speaker’s fee from Chugai, Mitsubishi Tanabe, outside the submitted work. MK reports grants from GSK, grants from Actelion, outside the submitted work. The other authors state that they have no conflict of interest.

Supplementary material

296_2019_4370_MOESM1_ESM.docx (19 kb)
Supplementary material 1 (DOCX 19 kb)
296_2019_4370_MOESM2_ESM.docx (53 kb)
Supplementary material 2 (DOCX 54 kb)

References

  1. 1.
    Tyndall AJ, Bannert B, Vonk M, Airo P, Cozzi F, Carreira PE et al (2010) Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 69(10):1809–1815CrossRefGoogle Scholar
  2. 2.
    Morrisroe K, Stevens W, Huq M, Prior D, Sahhar J, Ngian GS et al (2017) Survival and quality of life in incident systemic sclerosis-related pulmonary arterial hypertension. Arthritis Res Ther 19(1):122CrossRefGoogle Scholar
  3. 3.
    Kato M, Atsumi T (2018) Pulmonary arterial hypertension associated with connective tissue diseases: a review focusing on distinctive clinical aspects. Eur J Clin Invest 48(2):e12876CrossRefGoogle Scholar
  4. 4.
    Coghlan JG, Denton CP, Grunig E, Bonderman D, Distler O, Khanna D et al (2014) Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 73(7):1340–1349CrossRefGoogle Scholar
  5. 5.
    Guillen-Del Castillo A, Callejas-Moraga EL, Garcia G, Rodriguez-Palomares JF, Roman A, Berastegui C et al (2017) High sensitivity and negative predictive value of the DETECT algorithm for an early diagnosis of pulmonary arterial hypertension in systemic sclerosis: application in a single center. Arthritis Res Ther 19(1):135CrossRefGoogle Scholar
  6. 6.
    Vandecasteele E, Drieghe B, Melsens K, Thevissen K, De Pauw M, Deschepper E et al (2017) Screening for pulmonary arterial hypertension in an unselected prospective systemic sclerosis cohort. Eur Respir J 49(5):1–9CrossRefGoogle Scholar
  7. 7.
    Valerio CJ, Schreiber BE, Handler CE, Denton CP, Coghlan JG (2013) Borderline mean pulmonary artery pressure in patients with systemic sclerosis: transpulmonary gradient predicts risk of developing pulmonary hypertension. Arthritis Rheum 65(4):1074–1084CrossRefGoogle Scholar
  8. 8.
    Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M et al (2019) Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 53(1):1–13CrossRefGoogle Scholar
  9. 9.
    Bae S, Saggar R, Bolster MB, Chung L, Csuka ME, Derk C et al (2012) Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry. Ann Rheum Dis 71(8):1335–1342CrossRefGoogle Scholar
  10. 10.
    Humbert M, Yaici A, de Groote P, Montani D, Sitbon O, Launay D et al (2011) Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum 63(11):3522–3530CrossRefGoogle Scholar
  11. 11.
    Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA et al (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 30(20):2493–2537CrossRefGoogle Scholar
  12. 12.
    Thakkar V, Stevens WM, Prior D, Moore OA, Byron J, Liew D et al (2012) N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study. Arthritis Res Ther 14(3):R143CrossRefGoogle Scholar
  13. 13.
    Khanna D, Gladue H, Channick R, Chung L, Distler O, Furst DE et al (2013) Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension. Arthritis Rheum 65(12):3194–3201CrossRefGoogle Scholar
  14. 14.
    Hao Y, Thakkar V, Stevens W, Morrisroe K, Prior D, Rabusa C et al (2015) A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis. Arthritis Res Ther 17:7CrossRefGoogle Scholar
  15. 15.
    Sobanski V, Giovannelli J, Lynch BM, Schreiber BE, Nihtyanova SI, Harvey J et al (2016) Characteristics and survival of anti-U1 RNP antibody-positive patients with connective tissue disease-associated pulmonary arterial hypertension. Arthritis Rheumatol 68(2):484–493CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of MedicineHokkaido UniversitySapporoJapan
  2. 2.First Department of MedicineHokkaido University HospitalSapporoJapan

Personalised recommendations